Since 2011, new pharmacological therapies in Germany are subject to an early benefit assessment (EBA) upon launch by the Federal Joint Committee (G-BA). If a newly approved drug is not deemed to offer an additional benefit over available therapies by the G-BA, it is not granted premium-pricing, being subject to reference pricing. The G-BA can also put time limits on its resolutions, to conduct subsequent assessments based on newer/more mature evidence. This research aims to systematically analyze all time-limited G-BA resolutions.
Authors: Macaulay R, Majeed B, PAREXEL International, London, United Kingdom
To find out more about this poster you can register to download it here after the ISPOR event.